The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy
The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy
复制标题
胰腺导管腺癌个体化辅助化疗复发后生存时间的调查
DOI：
--
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Y. Doki
中科院分区：
文献类型：
--
作者：
Daisaku Yamada;H. Eguchi;Y. Iwagami;T. Asaoka;T. Noda;K. Kawamoto;K. Gotoh;Shogo Kobayashi;M. Mori;Y. Doki
PurposePancreatic ductal adenocarcinoma (PDAC) is a lethal disease; however, the frequency of recurrence can be reduced if curative surgery following adjuvant chemotherapy is applied. At present, adjuvant chemotherapy is uniformly performed in all patients, as it is unclear which tumor types are controlled best or worst. We investigated patients with recurrence to establish the optimum treatment strategy.MethodsOf 138 patients who underwent curative surgery for PDAC, 85 developed recurrence. Comprehensive clinicopathological factors were investigated for their association with the survival time after recurrence (SAR).ResultsThe median SAR was 12.6 months. Treatments for recurrence included best supportive care, GEM-based therapy and S-1. The performance status [hazard ratio (HR) 0.12, P < 0.001], histological invasion of lymph vessels (HR 0.27, P < 0.001), kind of treatment for recurrence (HR 5.0, P < 0.001) and initial recurrence site (HR 2.9, P < 0.001) were independent significant risk factors for the SAR. The initial recurrence sites were the liver (n = 21, median SAR 8.8 months), lung (n = 10, 14.9 months), peritoneum (n = 6, 1.7 months), lymph nodes (n = 6, 14.7 months), local site (n = 17, 13.9 months) and multiple sites (n = 25, 10.1 months). A shorter recurrence-free survival (< 1 year) and higher postoperative CA19-9 level were significantly associated with critical recurrence (peritoneal/liver).ConclusionsSeveral risk factors for SAR were detected in this study. Further investigations are needed to individualize the adjuvant chemotherapy for each patient with PDAC.
患者来源的乳腺癌模型中自发性肺转移的分化和恶性特征的丧失。
影响因子：
11.2
作者：
Bockhorn J;Prat A;Chang YF;Liu X;Huang S;Shang M;Nwachukwu C;Gomez-Vega MJ;Harrell JC;Olopade OI;Perou CM;Liu H
通讯作者：
Liu H